Drugs Show Promise in Reducing COPD Exacerbations While Beta-Blocker Trial Fails
New evidence indicates IL-33 inhibitors and GLP-1 drugs reduce exacerbations in COPD patients, whereas a beta-blocker trial fails to show benefit.
Sources
Every article we clustered into this story. Headlines link to the publisher.
- Can a Drug to Treat Lung Disease Slow Biological Aging? A 12-Week Trial Found Early Signs Inc.
- IL-33 Inhibitor Delivers in COPD Trials MedPageToday.com - medical news for physicians
- Asthma, COPD Attacks Down With GLP-1 Drugs in the Picture MedPageToday.com - medical news for physicians
- Beta-Blockers Hit With Another Negative Trial in COPD MedPageToday.com - medical news for physicians
In this story
- MedPage Today
- U.K.